Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Summary
Sapu Nano and Oncotelic Therapeutics expanded the Phase 1b development program for Sapu003 and named Global Clinical Trials as lead CRO for the international study. The program has moved beyond its initial Australian footprint and is now extending into Europe. GCT has already started regulatory coordination, site activation, logistics, and study management work. Sapu Nano says the expanded setup will support continued enrollment and prepare the program for future multinational Phase 3 development.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected